Clinical trial
CP-461 in the Treatment of Patients With Advanced Melanoma
NCT00060710 · Astellas Pharma Inc, Industry · Terminated
Key facts
| NCT number | NCT00060710 |
|---|---|
| Title | CP-461 in the Treatment of Patients With Advanced Melanoma |
| Official title | Phase II Study of CP-461 in the Treatment of Patients With Advanced Melanoma |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Cell Pathways Industry OSI Pharmaceuticals |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | CP-461 |
| Enrollment | 35 |
| Start date | Jan 1, 2003 |
| Completion | Dec 1, 2004 |
| First posted | May 13, 2003 |
| Last update posted | Oct 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: